ECSP22021725A - Prote?na VP1 modificada aislada de la c?pside del virus adeno-asociado de serotipo 5 (AAV5), c?pside y vector basado en la misma. - Google Patents
Prote?na VP1 modificada aislada de la c?pside del virus adeno-asociado de serotipo 5 (AAV5), c?pside y vector basado en la misma.Info
- Publication number
- ECSP22021725A ECSP22021725A ECSENADI202221725A ECDI202221725A ECSP22021725A EC SP22021725 A ECSP22021725 A EC SP22021725A EC SENADI202221725 A ECSENADI202221725 A EC SENADI202221725A EC DI202221725 A ECDI202221725 A EC DI202221725A EC SP22021725 A ECSP22021725 A EC SP22021725A
- Authority
- EC
- Ecuador
- Prior art keywords
- capsid
- aav5
- adeno
- associated virus
- vector based
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta solicitud se relaciona con los campos de la terapia g?nica y la biolog?a molecular. De manera m?s espec?fica, la presente invenci?n se refiere a una prote?na VP1 alterada aislada de la c?pside del virus adeno-asociado de serotipo 5 (AAV5), que comprende una o m?s sustituciones de amino?cidos en comparaci?n con la prote?na VP1 de la c?pside de AAV5 de tipo salvaje, que aumentan la eficiencia de transducci?n, as? como tambi?n se relaciona con una c?pside y un vector basado en la misma.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2019126509A RU2751592C2 (ru) | 2019-08-22 | 2019-08-22 | Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP22021725A true ECSP22021725A (es) | 2022-08-31 |
Family
ID=74660332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202221725A ECSP22021725A (es) | 2019-08-22 | 2022-03-21 | Prote?na VP1 modificada aislada de la c?pside del virus adeno-asociado de serotipo 5 (AAV5), c?pside y vector basado en la misma. |
Country Status (19)
Country | Link |
---|---|
US (1) | US20220306696A1 (es) |
EP (1) | EP4019642A4 (es) |
JP (1) | JP2022545121A (es) |
KR (1) | KR20220158674A (es) |
CN (1) | CN114981444A (es) |
AR (1) | AR119869A1 (es) |
AU (1) | AU2020331882A1 (es) |
BR (1) | BR112022003389A2 (es) |
CA (1) | CA3148964A1 (es) |
CO (1) | CO2022001833A2 (es) |
EC (1) | ECSP22021725A (es) |
IL (1) | IL290802A (es) |
JO (1) | JOP20220043A1 (es) |
MA (1) | MA56142B1 (es) |
MX (1) | MX2022002184A (es) |
PE (1) | PE20221254A1 (es) |
RU (1) | RU2751592C2 (es) |
TW (1) | TW202120690A (es) |
WO (1) | WO2021034222A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113121654B (zh) * | 2021-04-19 | 2023-11-17 | 信念医药科技(上海)有限公司 | 腺相关病毒衣壳蛋白及包含其的腺相关病毒载体 |
AR126839A1 (es) * | 2021-08-20 | 2023-11-22 | Llc «Anabion» | Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta |
AR126840A1 (es) | 2021-08-20 | 2023-11-22 | Llc «Anabion» | Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19827457C1 (de) * | 1998-06-19 | 2000-03-02 | Medigene Ag | Strukturprotein von AAV, seine Herstellung und Verwendung |
AU2002360291A1 (en) * | 2001-12-17 | 2003-06-30 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences |
RS60207B1 (sr) | 2011-04-22 | 2020-06-30 | Univ California | Adeno-povezani virioni virusa sa varijantama kapsida i postupci za njihovu primenu |
IN2014DN08812A (es) | 2012-04-18 | 2015-05-22 | Philadelphia Children Hospital | |
KR102380265B1 (ko) * | 2013-07-22 | 2022-03-29 | 더 칠드런스 호스피탈 오브 필라델피아 | 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도 |
US10081659B2 (en) * | 2015-04-06 | 2018-09-25 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Adeno-associated vectors for enhanced transduction and reduced immunogenicity |
PT3356390T (pt) * | 2015-09-28 | 2021-04-21 | Univ Florida | Métodos e composições para vetores virais que se evadem a anticorpos |
WO2017201121A1 (en) * | 2016-05-17 | 2017-11-23 | University Of Florida Research Foundation, Inc. | Recombinant aav for gene therapy in lungs |
-
2019
- 2019-08-22 RU RU2019126509A patent/RU2751592C2/ru active
-
2020
- 2020-08-21 CN CN202080074154.9A patent/CN114981444A/zh active Pending
- 2020-08-21 PE PE2022000294A patent/PE20221254A1/es unknown
- 2020-08-21 MX MX2022002184A patent/MX2022002184A/es unknown
- 2020-08-21 US US17/637,099 patent/US20220306696A1/en active Pending
- 2020-08-21 AU AU2020331882A patent/AU2020331882A1/en active Pending
- 2020-08-21 BR BR112022003389A patent/BR112022003389A2/pt unknown
- 2020-08-21 MA MA56142A patent/MA56142B1/fr unknown
- 2020-08-21 EP EP20855760.3A patent/EP4019642A4/en active Pending
- 2020-08-21 WO PCT/RU2020/000445 patent/WO2021034222A1/ru unknown
- 2020-08-21 JP JP2022512768A patent/JP2022545121A/ja active Pending
- 2020-08-21 KR KR1020227009552A patent/KR20220158674A/ko active Search and Examination
- 2020-08-21 JO JOP/2022/0043A patent/JOP20220043A1/ar unknown
- 2020-08-21 CA CA3148964A patent/CA3148964A1/en active Pending
- 2020-08-21 TW TW109128700A patent/TW202120690A/zh unknown
- 2020-08-31 AR ARP200102440A patent/AR119869A1/es unknown
-
2022
- 2022-02-21 CO CONC2022/0001833A patent/CO2022001833A2/es unknown
- 2022-02-22 IL IL290802A patent/IL290802A/en unknown
- 2022-03-21 EC ECSENADI202221725A patent/ECSP22021725A/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220158674A (ko) | 2022-12-01 |
US20220306696A1 (en) | 2022-09-29 |
CN114981444A (zh) | 2022-08-30 |
WO2021034222A9 (ru) | 2021-04-22 |
RU2751592C2 (ru) | 2021-07-15 |
MX2022002184A (es) | 2022-05-24 |
AR119869A1 (es) | 2022-01-19 |
JP2022545121A (ja) | 2022-10-25 |
BR112022003389A2 (pt) | 2022-05-17 |
CO2022001833A2 (es) | 2022-08-09 |
RU2019126509A (ru) | 2021-06-04 |
MA56142A1 (fr) | 2023-05-31 |
RU2019126509A3 (es) | 2021-06-04 |
JOP20220043A1 (ar) | 2023-01-30 |
EP4019642A1 (en) | 2022-06-29 |
TW202120690A (zh) | 2021-06-01 |
CA3148964A1 (en) | 2021-02-25 |
PE20221254A1 (es) | 2022-08-16 |
EP4019642A4 (en) | 2023-09-06 |
WO2021034222A1 (ru) | 2021-02-25 |
IL290802A (en) | 2022-04-01 |
MA56142B1 (fr) | 2023-09-27 |
AU2020331882A1 (en) | 2022-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP22021725A (es) | Prote?na VP1 modificada aislada de la c?pside del virus adeno-asociado de serotipo 5 (AAV5), c?pside y vector basado en la misma. | |
CL2019002474A1 (es) | Vector clado f de virus adeno-asociado (vaa) y usos relacionados. | |
EA201991911A1 (ru) | Способы и композиции для переноса генов по сосудистой сети | |
BR112019001532A2 (pt) | proteínas de capsídeo de vírus adenoassociado inovadoras | |
CL2023000264A1 (es) | Nuevos vectores virales adeno-asociados dirigidos al hígado | |
CL2020000728A1 (es) | Variantes de cápsides de virus adenoasociados y métodos de uso de estas. | |
UA124343C2 (uk) | Капсиди аденоасоційованого вірусу і спосіб його використання | |
PE20160188A1 (es) | Variantes aav y composiciones, metodos y usos para transferencia de gen a celulas, organos y tejidos | |
BR112021020054A2 (pt) | Capsídeos de vírus adeno-associado (aav) e composições contendo os mesmos | |
BR112018011975A2 (pt) | composições úteis no tratamento de atrofia muscular espinhal | |
CO2021016200A2 (es) | Composiciones útiles para el tratamiento de la enfermedad de pompe | |
EA202091712A1 (ru) | МОДИФИЦИРОВАННЫЙ КАПСИДНЫЙ БЕЛОК rAAV ДЛЯ ГЕННОЙ ТЕРАПИИ | |
UY37863A (es) | Virus adenoasociado (aav) con dominio de fosfolipasa modificado | |
PE20121171A1 (es) | Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos | |
CO2023015564A2 (es) | Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv | |
CO2024001457A2 (es) | Proteína de la cápside vp1 modificada aislada aav9 | |
AR123369A1 (es) | VACUNA BASADA EN AAV5 PARA LA INDUCCIÓN DE INMUNIDAD ESPECÍFICA CONTRA EL SARS-CoV-2 Y/O LA PREVENCIÓN DE LA INFECCIÓN POR CORONAVIRUS RELACIONADA CON EL SARS-CoV-2 | |
AR126840A1 (es) | Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta | |
EA201290384A1 (ru) | Вирусные цитруллинированные пептиды и их применение | |
EA200802101A1 (ru) | Конструкции-"шпильки" р15 и применение | |
EA202091194A1 (ru) | Вирусные векторы, содержащие области, кодирующие rdh12, и способы лечения дистрофий сетчатки | |
CO2024001455A2 (es) | Sistema de expresión de baculovirus | |
EA201990955A1 (ru) | Разработка капсидов aav | |
UY39659A (es) | Ácido nucleico optimizado por codones que codifica la proteína del factor de coagulación ix y su uso | |
EA202092654A1 (ru) | Генная терапия сердца с помощью aav при кардиомиопатии |